

1 **Higher ratio of plasma omega-6/omega-3 fatty acids is associated**
2 **with greater risk of all-cause, cancer, and cardiovascular mortality:**
3 **a population-based cohort study in UK Biobank**

4
5 **Authors:** Yuchen Zhang, MSPH¹; Yitang Sun, MPH²; Qi Yu, MSPH³, Suhang Song, PhD⁴, J.
6 Thomas Brenna, PhD^{5,6}; Ye Shen, PhD^{1*}; Kaixiong Ye, PhD^{2,7*}

7
8 **Author Affiliations:**

9 ¹ Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia,
10 Athens, Georgia, US

11 ² Department of Genetics, University of Georgia, Athens, Georgia, US

12 ³ Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, US

13 ⁴ Department of Health Policy and Management, College of Public Health, University of Georgia,
14 Athens, Georgia, US

15 ⁵ Division of Nutritional Sciences, Cornell University, Ithaca, NY, US

16 ⁶ Dell Pediatric Research Institute and the Depts of Pediatrics, of Nutrition, and of Chemistry,
17 University of Texas at Austin, Austin, TX, US

18 ⁷ Institute of Bioinformatics, University of Georgia, Athens, Georgia, US

19 * YS and KY jointly supervised this project.

20

21 **Corresponding Author:**

22 Kaixiong Ye, PhD

23 Department of Genetics, C220 Davison Life Sciences Complex, University of Georgia, 120 East
24 Green Street, Athens, GA 30602

25 Phone: 706-542-5898 Email: kaixiong.ye@uga.edu

26 Ye Shen, PhD

27 Department of Epidemiology and Biostatistics, University of Georgia, 101 Buck Rd, Athens, GA
28 30602

29 Phone: 706-542-2754 Email: yeshen@uga.edu

30 **Abstract**

31 **Background**

32 Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated
33 with various chronic diseases and mortality, but results are conflicting. Few studies examined the
34 role of omega-6/omega-3 ratio in mortality.

35 36 **Methods**

37 We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and
38 cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants
39 who had complete information on circulating PUFAs, 6,461 died during follow-up, including
40 2,794 from cancer and 1,668 from cardiovascular disease (CVD). Associations were estimated
41 by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.

42 43 **Results**

44 Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs
45 increased (all $P_{\text{trend}} < 0.05$). Comparing the highest to the lowest quintiles, individuals had 26%
46 (95% CI, 15-38%) higher total mortality, 14% (95% CI, 0-31%) higher cancer mortality, and 31%
47 (95% CI, 10-55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma
48 were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing
49 stronger effects.

50 51 **Conclusions**

52 Using a population-based cohort in UK Biobank, our study revealed a strong association between
53 the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD
54 mortality.

55 56 **Keywords**

57 Polyunsaturated fatty acids, Omega-3 fatty acids, Omega-6 fatty acids, Mortality, Prospective
58 studies

59

60 **Background**

61
62 Cancer and cardiovascular disease (CVD) are the two leading causes of non-communicable
63 disease mortality globally¹. Substantial epidemiologic evidence has linked the dietary or
64 circulating levels of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) to the risks of
65 all-cause, cancer, and CVD mortality (**Additional file 1: Table S1**). However, the results are
66 inconsistent, especially for omega-6 PUFAs. Most large observational studies support the inverse
67 associations between omega-3 PUFAs and mortality. In addition to total and individual omega-3
68 PUFAs, the omega-3 index, defined as the percentage of eicosapentaenoic acid (EPA) and
69 docosahexaenoic acid (DHA) in total fatty acids in red blood cells, was shown to be a validated
70 biomarker of the dietary intake and tissue levels of long-chain omega-3 PUFAs, and was
71 proposed to be a risk factor for CVD and related mortality^{2,3}. While the omega-3 index has been
72 observed to be inversely associated with all cause-mortality, its association patterns with CVD
73 and cancer mortality are less clear⁴⁻⁶. Most importantly, results from clinical trials of omega-3
74 PUFA supplementation have been inconsistent^{7,8}. On the other hand, while some studies revealed
75 inverse associations of omega-6 PUFAs with all-cause mortality⁹⁻¹¹, others reported null
76 results^{4,12-15}. The role of omega-6 PUFAs in cancer and CVD mortality is less studied, and the
77 patterns are similarly conflicting^{4,9-11}. Interpreting previous observational results is challenging
78 due to the limitations of small sample sizes, insufficient adjustments for confounding, and unique
79 sample characteristics. Moreover, many studies rely on self-reported dietary intake or fish oil
80 supplementation status, which are subject to large variability and reporting bias¹⁶. Despite the
81 tremendous interest and research effort, the roles of omega-3 and omega-6 PUFAs in all-cause
82 and cause-specific mortality remain uncertain.

83

84 It has been suggested that the high omega-6/omega-3 ratio in Western diets, 20:1 or even higher,
85 as compared to an estimated 1:1 during the most time of human evolution, contributes to many
86 chronic diseases, including CVD, cancer, and autoimmune disorders^{17,18}. However, while many
87 previous studies have examined total or individual omega-3 and omega-6 PUFAs, fewer
88 investigated the role of their imbalance, as measured by the omega-6/omega-3 ratio, in
89 mortality^{4,14,15,19}. In a prospective cohort study of postmenopausal women, the omega-6/omega-3
90 ratio in red blood cells was associated with an increased risk of all-cause mortality but not with
91 cancer or CVD mortality⁴. Similar positive associations with all-cause mortality were observed
92 in smaller cohorts investigating the ratio in serum or dietary intake^{14,19}. However, prospective
93 studies in two independent cohorts from China and US did not find a linear positive association
94 between the omega-6/omega-3 ratio in diet and all-cause mortality¹⁵. To address these gaps in
95 our understanding of the roles of omega-3 and omega-6 PUFAs and their imbalance in all-cause
96 and cause-specific mortality, we perform a prospective study in a large population-based cohort
97 (N = 85,425) from UK Biobank, using objective measurements of PUFA levels in plasma.

98

99 **Methods**

100 *Study population*

101 The UK Biobank study is a prospective, population-based cohort study in the United Kingdom²⁰.
102 Between 2006 and 2010, 502,384 prospective participants, aged 40-69, in 22 assessment Centers
103 throughout the UK were recruited for the study. The population information was collected
104 through a self-completed touch-screen questionnaire; brief computer-assistant interview;
105 physical and functional measures; and blood, urine, and saliva collection during the assessment
106 visit. Participants with cancer (n=37,736) or CVD (n=100,972), those who withdrew from the

107 study (n=879), and those with incomplete data on the plasma omega-6/omega-3 ratio (n=277,372)
108 were excluded from this study, leaving 85,425 participants, 6,461 died during follow-up,
109 including 2,794 from cancer and 1,668 from CVD.

110

111 *Ascertainment of exposure*

112 Metabolomic profiling of plasma samples was performed with high-throughput nuclear magnetic
113 resonance (NMR) spectroscopy. At the time of this analysis (15 Mar 2023), UK Biobank
114 released the Phase 1 metabolomic dataset, which covered a random selection of 118,461 plasma
115 samples from the baseline recruitment. These samples were collected between 2007 and 2010
116 and had been stored in -80°C freezers, while the NMR measurements took place between 2019
117 and 2020. . Detailed descriptions can be found in previous publications about plasma sample
118 preparation, NMR spectroscopy setup, quality control protocols, correction for sample dilution,
119 verification with duplicate samples and internal controls, and comparisons with independent
120 measurements from clinical chemistry assays²⁰⁻²². Five PUFAs-related biomarkers were directly
121 measured in absolute concentration units (mmol/L), including total PUFAs, total omega-3
122 PUFAs, total omega-6 PUFAs, docosahexaenoic acid (DHA), and linoleic acid (LA). Of note,
123 DHA is one type of omega-3 PUFAs, and LA is one type of omega-6 PUFAs. Our primary
124 exposure of interest, the omega-6/omega-3 ratio, was calculated based on their absolute
125 concentrations. We also performed supplemental analysis for four exposures, the percentages of
126 omega-3 PUFAs, omega-6 PUFAs, DHA, and LA in total fatty acids (omega-3%, omega-6%,
127 DHA%, and LA%), which were calculated by dividing their absolute concentrations to that of
128 total fatty acids.

129 *Ascertainment of outcome*

130 The date and cause of death were identified through the death registries of the National Health
131 Service (NHS) Information Centre for participants from England and Wales and the NHS Centre
132 Register Scotland for participants from Scotland²⁰. At the time of the analysis (15 Mar 2023), we
133 had access to the most up-to-date mortality dataset (Version: December 2022), which had the
134 date of death up to 12 November 2021. Therefore, follow-up time was calculated as the time
135 between the date of entering the assessment centre and this date, or the date of death, whichever
136 happened first. The underlying cause of death was assigned and coded in vital registries
137 according to the International Classification of Diseases, 10th revision (ICD-10). CVD mortality
138 was defined using codes I00-I99, and cancer mortality was defined using codes C00-D48. To
139 exclude those who had cancer at baseline, we used the overall cancer incidence information
140 based on diagnoses in cancer registers derived from the Health and Social Care Information
141 Centre and the NHS Central Register that were coded based on ICD-9 and ICD-10 codes. The
142 information about CVD incidence was retrieved from Hospital inpatient data and Death Register
143 records that were coded according to ICD-9 and ICD-10 codes, and self-reported medical
144 condition.

145

146 *Ascertainment of covariates*

147 The baseline questionnaire included detailed information on several possible confounding
148 variables: demographic factors (age, sex, assessment centre, ethnicity), socioeconomic status
149 (Townsend Deprivation Index), lifestyle habits (alcohol assumption, smoking status, body mass
150 index (BMI), physical activity, comorbidities (including hypertension, diabetes, and
151 longstanding illness)), and other supplementation (Fish-oil supplementation). The Townsend
152 Deprivation Index, used as an indicator of socioeconomic status, is retrieved directly from the

153 UK Biobank. BMI was defined as the body mass divided by the square of the body height and
154 was expressed in units of kg/m^2 . Comorbidities, including hypertension, diabetes, and
155 longstanding illness, were self-reported at baseline. Longstanding illness refers to any long-
156 standing illness, disability, or infirmity, without other specific information. We also retrieved the
157 information on dietary PUFA intakes and serum biomarkers for secondary analysis. Dietary
158 PUFAs were estimated based on the 24-hour dietary recall²³. The percentage of dietary omega-3
159 and omega-6 PUFA were calculated as the corresponding absolute dietary PUFA divided by
160 summation of dietary monounsaturated fatty acids, saturated fatty acids, omega-3 fatty acids, and
161 omega-6 fatty acids. The biochemistry markers were measured in the blood sample collected at
162 recruitment.

163

164 *Statistical analysis*

165 We summarized and compared the characteristics of the participants across quintiles of the
166 omega-6/omega-3 ratio at baseline using descriptive statistics. Pearson's Chi-squared test and
167 ANOVA test were used to compare the demographic characteristics across quintiles, respectively,
168 for categorical variables and continuous variables. To investigate associations of the ratio with
169 all-cause and cause-specific mortality, we used multivariable Cox proportional hazards
170 regression models to calculate hazard ratios²⁴ and their 95% confidence intervals (CI). The
171 proportional hazards assumption was not violated based on Schoenfeld residuals. We analyzed
172 the ratio as continuous and categorical variables (i.e., quintiles). For all trend tests, we used the
173 median value of each quintile as a continuous variable in the models. Potential nonlinear
174 associations were assessed semi-parametrically using restricted cubic splines (4 knots were used
175 in regression splines)²⁵.

176

177 Based on previous literature and biological plausibility^{11,26,27}, we chose the following variables
178 as covariates in the multivariate models: age (years; continuous), sex (male, female), race (White,
179 Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI
180 (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never,
181 previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

182

183 In secondary analyses to assess potential differences in associations across different population
184 subgroups, we repeated the above-described analyses stratified by age (< vs. ≥ the median age of
185 58 years), sex (male/female), Townsend deprivation index (< vs. ≥ the population median of -2),
186 BMI ((< vs. ≥ 25), comorbidities (yes vs. no), physical activity (low and moderate vs. high) and
187 current smoking status (yes vs. no). Besides, to compare the effects of dietary intake of PUFAs
188 with the plasma levels on mortality, we repeated the above-described analyses in participants
189 with complete information on dietary intake PUFAs (N=153,064). Moreover, we conducted
190 mediation analysis to investigate potential biological pathways that might explain the effects of
191 omega-6/omega-3 ratio on mortality outcomes. Based on plausibility, we chose CRP as a
192 potential mediating factor for CVD mortality; SHBG, TTST, E2 and IGF-1 as potential
193 mediating factors for cancer mortality; and all the above biomarkers for all-cause mortality. We
194 first examined the variations in the concentrations of each biomarker according to omega-
195 6/omega-3 ratio quintiles. Then we constructed two regression models, a linear model, to regress
196 the mediator (treated the biomarkers as continuous) on the exposure (treated the omega-6/omega-
197 3 ratio as continuous), with fully-adjustment for potential confounders; and a Cox proportional
198 hazard model, to regress the outcome (mortality outcomes) on the exposure and the mediator,

199 with fully-adjustment for potential confounders. We chose to construct Cox models for
200 mediation analysis because our outcomes were rare (all <10%)²⁸. We integrated these two
201 regression models to obtain the indirect effects and proportions of mediating effects through the
202 counterfactual-based approach proposed by Vander Weele^{29,30}.

203
204 We also conducted several sensitivity analyses. First, to assess whether the associations of the
205 omega-6/omega-3 ratio with mortality outcomes were primarily driven by omega-3 fatty acids or
206 omega-6 fatty acids, we assessed both the separate and the joint associations of omega-3 fatty
207 acids to total fatty acids percentage (omega-3%) and omega-6 fatty acids to total fatty acids
208 percentage (omega-6%) with the three mortality outcomes. We also performed a joint analysis
209 with categories of the omega-3% and omega-6% quintiles, using participants in both the lowest
210 omega-3% and omega-6% quintiles as the reference category. An interaction term between
211 omega-3% and omega-6% was included in the multivariable Cox proportional hazards model,
212 and a Likelihood Ratio test was used to assess its significance. The correlation between omega-3%
213 and omega-6% was assessed by the Pearson correlation. Second, to assess the effects of
214 individual PUFAs on mortality, we conducted the same analysis for circulating docosahexaenoic
215 acid to total fatty acids percentage (DHA%) and linoleic acid to total fatty acids percentage
216 (LA%) with the three mortality outcomes. Third, to address the potential residual confounding
217 by fish oil supplementation, we further adjusted for the supplementation status from the baseline
218 questionnaire. Fourth, to investigate the effects of missing values, we imputed missing values
219 (<1% for most factors, up to 19% for physical activity) by chained equations and performed
220 synthesis analyses on the imputed datasets³¹. Fifth, to assess whether the observed associations
221 are attenuated by reverse causation, we excluded those who died in the first year of follow-up.

222 Last, to assess the representativeness of the participants included in our study, we compared the
223 baseline characteristics between the participants with and without exposure information. All P-
224 values were two-sided. We considered a P-value <0.05 or a 95% confidence interval (CI)
225 excluding 1.0 for HRs as statistically significant. We conducted all analyses using R, version
226 4.0.3 and SAS statistical software, version 9.4 (SAS Institute Inc.).

227

228 **Results**

229 *Baseline characteristics*

230 In the analytic cohort of 85,425 participants, over a mean of 12.7 years of follow-up, 6,461 died,
231 including 2,794 from cancer and 1,668 from CVD. The baseline characteristics of the
232 participants across quintiles of the ratio of omega-6/omega-3 were summarized in **Table 1**. Study
233 participants were, on average, 56 years old and 90% White. Those in the higher ratio quintiles
234 were more likely to be younger, male, and current smokers, but less likely to have comorbidities
235 and take fish oil supplementation.

236

237 *Main results*

238 The associations of the omega-6/omega-3 ratio with all-cause and cause-specific mortality risks
239 were presented in **Table 2**. A higher ratio was strongly associated with higher mortality from all
240 causes, cancer, and CVD ($P_{\text{trend}} < 0.05$ for all three). In the fully adjusted models that considered
241 the ratio as a continuous variable, every unit increase in the ratio corresponded to 2%, 1%, and 2%
242 higher risk in all-cause, cancer, and CVD mortality, respectively. When comparisons were made
243 between the highest and the lowest quintile of the omega-6/omega-3 ratio, there were 26%, 14%,
244 and 31% increased risk for all-cause, cancer, and CVD mortality, respectively.

245

246 *Stratified analysis*

247 The fully adjusted associations of the omega-6/omega-3 ratio with all-cause mortality revealed
248 that compared to the lowest quintile, the highest quintile has strong, statistically significant
249 associations with elevated risk within all categories of age, sex, TDI, BMI, comorbidities,
250 physical activity, and smoking status (**Figure 1, Additional file 2: Table S2**), except in those
251 aged less than 58 years old and BMI less than 25. The estimated associations with all-cause
252 mortality were stronger in current smokers (P for interaction < 0.01; **Figure 1, Additional file 2:**
253 **Table S2**). For cancer and CVD mortality, they also tended to be stronger among current
254 smokers but did not reach statistical significance (P for interaction = 0.13 and 0.12, respectively).
255 The associations with CVD mortality tended to be stronger among participants without
256 comorbidities (P for interaction <0.01). No significant interactions were found for other risk
257 factors (**Figure 2**).

258

259 *Restricted cubic spline analysis*

260 Restricted cubic spline analysis suggested significant positive associations of the omega-
261 6/omega-3 ratio with all-cause, cancer, and CVD mortality (P < 0.05 for all three outcomes,
262 **Figure 3**). Potential nonlinearity in these positive associations was identified for all-cause
263 mortality (P < 0.05) and CVD mortality (P < 0.05) but not for cancer mortality (P = 0.12). The
264 strength of the relationship between the ratio and all-cause mortality appears to remain at a
265 relatively low level before it starts to increase quickly after the ratio exceeds 8. A similar trend
266 with higher uncertainties was observed for CVD mortality.

267

268 *Omega-3, Omega-6, Joint analysis, and comparison with dietary PUFAs*

269 We further performed analyses to assess whether the associations of the omega-6/omega-3 ratio
270 with mortality outcomes were primarily driven by omega-3 or omega-6 fatty acids. The
271 correlation between omega-3% and omega-6% was relatively low with $r = -0.12$ ($P < 0.01$).
272 Across all models, both the omega-3% and omega-6% were inversely associated with all three
273 mortality outcomes, except for plasma omega-6% with CVD mortality under Model 3 ($P_{\text{trend}} <$
274 0.01 , **Additional file 2: Table S3 and Table S4**). Notably, their associations remained
275 significant when they were included in the same models. On the other hand, the effect sizes of
276 the inverse associations were always bigger for the omega-3% under the fully adjusted Model 3.
277 For example, when comparing those in the highest omega-3% quintile to the lowest quintile, the
278 fully adjusted HRs (95% CI) for all-cause, cancer, and CVD mortality were, respectively, 0.69
279 (0.63, 0.76), 0.75 (0.65, 0.87), and 0.68 (0.57, 0.82) (**Additional file 2: Table S3**). The
280 corresponding HRs for the omega-6% were 0.77 (0.70, 0.85), 0.80 (0.68, 0.92), and 0.83 (0.68,
281 1.02) (**Additional file 2: Table S4**). Furthermore, in another joint analysis of the omega-3% and
282 omega-6%, the lowest risk for all-cause and cancer mortality was observed among those in the
283 joint highest categories of the two fatty acids (**Additional file 2: Table S5**). For example, when
284 comparing those in the highest quintiles of the two fatty acids to the group with the joint lowest
285 group, the HRs (95% CI) for all-cause and cancer mortality were, respectively, 0.48 (95% CI,
286 0.35, 0.67) and 0.53 (95% CI, 0.33, 0.86). In the analysis of dietary PUFAs with mortality, the
287 effect sizes were smaller and less significant compared with those of the corresponding plasma
288 levels. When analyzed as continuous variables, dietary omega-3%, omega-6% and omega-
289 6/omega-3 ratio were all significantly associated with all-cause, cancer, and CVD mortality, in
290 directions consistent with their plasma counterparts. The trend test across the five quintiles

291 revealed significant associations between dietary omega-3% and omega-6/omega-3 ratio with
292 cancer mortality (P for trend < 0.001 and = 0.002, respectively; **Additional file 2: Table S6**). The
293 correlation between dietary omega-3% and omega-6% was $r = 0.41$ ($P < 0.01$).

294

295 *Mediation analysis for intermediate biomarkers*

296 The baseline serum biomarkers of the participants across quintiles of the ratio of omega-
297 6/omega-3 were summarized in **Additional file 2: Table S7**. The estimates for the three paths a
298 (association between plasma omega-6/omega-3 ratio and biomarkers), b (association between
299 biomarkers and mortality outcomes), and c (association between plasma omega-6/omega-3 ratio
300 and mortality outcomes), as well as the percentage of indirect effect (a to b) among the overall
301 associations, were reported in **Additional file 2: Table S8 and Figure S1**. These analyses
302 identified CRP and SHBG as potential mediators for the association of plasma omega-6/omega-3
303 ratio with all-cause mortality (proportion of mediating = 4% and 5.0%, respectively).

304 *Other sensitivity analyses*

305 We performed analyses to examine the associations of DHA% and LA% with mortalities. The
306 correlation between DHA% and LA% was relatively low with $r = 0.03$ ($P < 0.01$). Under the
307 fully-adjusted model, both DHA% and LA% were inversely associated with all three mortality
308 outcomes, regardless of treated as continuous or quintiles (**Additional file 2: Table S9**). After
309 further adjustment of the fish oil supplementation status, the associations between the ratio of
310 omega-6/omega-3 and mortality outcomes were slightly attenuated yet did not alter the main
311 findings (**Additional file 2: Table S10**). Our primary analysis excluded participants with
312 missing information (i.e., a complete-case analysis). We performed a sensitivity analysis using
313 the multiply-imputed datasets, and there were no substantial changes (**Additional file 2: Table**

314 **S11**). Moreover, the exclusion of participants who died during their first-year follow-up did not
315 materially alter the results (**Additional file 2: Table S12**). The baseline characteristics are
316 comparable between participants with or without exposure information (**Additional file 2: Table**
317 **S13**).

318

319 **Discussion**

320 In this prospective population-based study of UK individuals, we showed that a higher ratio of
321 plasma omega-6/omega-3 fatty acids was positively associated with the risk of all-cause, cancer,
322 and CVD mortality. These associations were independent of most risk factors examined,
323 including age, sex, TDI, BMI, comorbidities, and physical activity, but they were stronger in
324 current smokers. These relationships were linear for cancer mortality but not for all-cause and
325 CVD mortality. For those two outcomes, the risk of mortality first decreased at lower ratios and
326 then increased, with an inflection point around the ratio of 8. Moreover, omega-3 and omega-6
327 PUFAs in plasma were consistently and inversely associated with all-cause, cancer, and CVD
328 mortality, with omega-3 showing stronger effects.

329

330 To date, studies that examined the relationship between the ratio of omega-6/omega-3 PUFAs
331 and mortality in the general population are sparse^{4,14,15,19}. Similar to our finding, in a 2017 report
332 from a prospective women cohort study (n=6,501; 1,875 all-cause deaths, 617 CVD deaths, 462
333 cancer deaths)⁴, the adjusted HR for all-cause mortality was 1.10 (1.02-1.19) per 1-SD increase
334 of omega-6/omega-3 ratio in red blood cells, however, the effects were not significant for cancer
335 and CVD deaths. Another study supporting our results was conducted on elderly Japanese
336 individuals (n=1,054; 422 deaths). It found that the ratio of an omega-3 fatty acid,

337 eicosapentaenoic acid, to an omega-6 fatty acid, arachidonic acid (ARA), is inversely associated
338 with all-cause mortality, with an HR of 0.71 (95% 0.53–0.96) comparing the highest to the
339 lowest tertile¹⁴. Findings of previous studies based on dietary intake were null^{15,19}. A prospective
340 cohort involving 145 hemodialysis patients enrolled in Southern California during 2001-2007
341 (42 all-cause deaths) showed that the estimated HR (95% CI) for all-cause mortality among those
342 in the lowest relative to the highest quartiles of dietary omega-6/omega-3 ratio was 0.37 (0.14-
343 1.08)¹⁹. Although the effect was not significant, it still shows the protective trend of a lower
344 omega-6/omega-3 ratio against premature death, when taking the sample size and study
345 population into consideration. In a 2019 report based on two population-based prospective
346 cohorts in China (n=14,117, 1,007 all-cause deaths) and the US (n=36,032, 4,826 all-cause
347 deaths), the effect of the omega-6/omega-3 ratio intake was not significant (HR (95% CI) is 0.95
348 (0.80-1.14) for China and 0.99 (0.89-1.11) for US, respectively)¹⁵. These discrepancies may be
349 explained by the usage of circulating biomarkers or dietary intakes for calculating the omega-
350 6/omega-3 ratio. Indeed, we performed the same association analyses for dietary PUFAs and
351 found that their associations with mortality have smaller effect sizes and are less statistically
352 significant, although maintaining the same effect directions as plasma PUFAs. The estimated
353 dietary intakes may be inaccurate due to recall bias or outdated food databases¹⁶. The circulating
354 level is a more objective measurement of PUFA status and thus provides a more reliable picture
355 of the effects of omega-3 and omega-6 PUFAs on mortality. Additionally, we observed that the
356 omega-6/omega-3 ratio tends to have stronger effects on mortality outcomes in current smokers.
357 This is consistent with a previous observation that the association between habitual fish oil
358 supplementation and a lower risk of all-cause mortality is stronger in current smokers²⁶.
359 Moreover, we found that current smokers in UK Biobank tend to have higher omega-6/omega-3

360 ratios. Similarly, prior studies reported that current smokers have lower circulating omega-3
361 PUFAs than non-smokers but similar circulating levels of omega-6 PUFAs^{32,33}. It is likely that
362 omega-3 PUFAs play more important roles in current smokers, resulting in a stronger effect of
363 the omega-6/omega-3 ratio on mortality. However, the underlying mechanism awaits future
364 investigations.

365
366 A large number of existing observational studies documented the inverse association of
367 circulating levels and intake of omega-3 PUFAs with mortality^{5,6,27,34-39}, which is in line with our
368 finding that individuals in the highest quintile of the plasma omega-3% had approximately 30%
369 lower risk for all-cause and CVD mortality and 25% lower risk for cancer mortality, when
370 compared to those in the lowest quintile. Our analysis of dietary omega-3% also revealed inverse
371 associations with all-cause and cancer mortality, with 9% and 18% lower risk, respectively. Few
372 previous studies have examined the association in generally healthy populations^{5,27,34,36}. In a
373 2016 meta-analysis³⁴ of seven epidemiologic studies for dietary omega-3 PUFAs intake and four
374 studies for circulating levels, the estimated relative risk for all-cause mortality was 0.91 (95% CI:
375 0.84-0.98) when comparing the highest to the lowest categories of omega-3 PUFA intake. In two
376 2018 reports of population-based studies in the US, the circulating level and dietary intake of
377 omega-3 PUFAs were significantly associated with lower total mortality^{5,27}. In a 2021 meta-
378 analysis of 17 epidemiologic studies, comparing the highest to the lowest quintiles of circulating
379 EPA and DHA, the estimated HRs for all-cause, CVD, and cancer mortality were 0.84 (0.79-
380 0.89), 0.80 (0.73-0.88) and 0.87 (0.78-0.96), respectively³⁶. Moreover, inverse associations of
381 omega-3 PUFAs biomarkers with total mortality were found in patients with myocardial
382 infarction^{37,39}, type 2 diabetes¹², and other diseases^{6,35,38,40}; inverse associations of omega-3

383 PUFAs with CVD mortality were also reported in these patient groups^{6,12,39}. However, there are
384 also reports of a null relationship between omega-3 PUFAs and mortality^{13,14,41}. One possible
385 explanation for the discrepancies could be the limited statistical power due to the small sample
386 size and the small number of events. Moreover, the inconsistency may be due to unique sample
387 characteristics; one study only involved elder patients¹⁴, and one only involved women⁴¹.

388
389 A smaller number of studies have evaluated the associations of omega-6 PUFAs with mortality.
390 Our findings in the large UK prospective cohort are in accordance with the results of several
391 previous studies that increased circulating levels of omega-6 PUFAs were associated with
392 decreased all-cause mortality^{9,11,15,42}. Moreover, a 2019 meta-analysis involving 18 cohort
393 studies and 12 case-control studies showed that an omega-6 PUFA, linoleic acid, was inversely
394 associated with CVD mortality; the HR per interquintile range was 0.78 (95% CI, 0.70-0.85)¹⁰.
395 Other studies, however, did not support such inverse associations^{4,12-14,41}. Although the findings
396 were inconsistent, no previous studies reported harmful effects of omega-6 PUFAs on
397 mortality^{4,11-15,41-44}. Our studies support the inverse associations between omega-6 PUFAs and
398 all-cause and cause-specific mortality. Further research is needed to investigate the health
399 impacts of omega-6 PUFAs in laboratory studies, epidemiological investigations, and clinical
400 trials.

401
402 We observed that the omega-6/omega-3 ratio is positively, while both of its numerator and
403 denominator, omega-6% and omega-3%, are negatively associated with mortality. Our findings
404 support that both omega-6 and omega-3 PUFAs are protective against death and that the positive
405 associations of the omega-6/omega-3 ratio with mortality outcomes are likely due to the stronger

406 effects of omega-3 than omega-6 PUFAs. Our mediation analysis with clinical biomarkers for
407 CVD and cancer revealed that CRP and SHBG partially mediated the effects of the omega-
408 6/omega-3 ratio on all-cause mortality. However, the proportions mediated are relatively small
409 (~5%), suggesting the presence of direct effects or unexamined factors. Our findings call for
410 future studies that evaluate the utility and investigate the mechanisms of the omega-6/omega-3
411 ratio.

412
413 Strengths of our current study include the use of objective PUFA biomarkers in plasma instead
414 of the estimated intakes from dietary questionnaires, which increases the accuracy of exposure
415 assessment. Moreover, the prospective population-based study design, large sample size, long
416 duration of follow-up, and detailed information on potential confounding variables, substantially
417 mitigate the possible complications from reverse causality and confounding bias. In several
418 sensitivity analyses, most of the documented associations remain materially unchanged,
419 indicating the robustness of our results.

420
421 Several potential limitations deserve attention. First, plasma omega-3 and omega-6 PUFAs were
422 measured only once at baseline. Their levels may vary with diet or other lifestyle factors, which
423 could cause misclassification over follow-up. However, some studies demonstrated that multiple
424 measurements of omega-3 PUFAs have been consistent for a 6-month period⁴⁵. Moreover, the
425 13-year within-person correlation for circulating omega-6 PUFAs was comparable to such
426 correlations for other major CVD risk factors⁴⁶. Thus, the single measurement of PUFAs at
427 baseline, although not perfect, provides us with adequate information to investigate the relative
428 long-term effects. Second, although we adjusted for many potential confounders in the model,

429 we cannot rule out the imprecisely measured and unmeasured factors. Third, we acknowledged
430 that the cohort did not mirror the broader UK demographic in terms of socioeconomic and health
431 profiles. Participants in the UK Biobank generally exhibited better health and higher
432 socioeconomic status than the average UK resident, potentially influencing the disease
433 prevalence and incidence rates. Nonetheless, the UK Biobank's extensive sample size and
434 comprehensive exposure data enable the generation of valuable estimates for exposure-disease
435 associations. These estimates have been corroborated by findings from more demographically
436 representative cohorts^{47,48}. Last, although we included individuals of different ancestries in the
437 analysis, over 90% of the participants were of European ancestry. The generalizability of our
438 findings across ancestries requires future verification.

439

440 **Conclusions**

441 In this large prospective cohort study, we documented robust positive associations of the plasma
442 omega-6/omega-3 fatty acids ratio with the risk of all-cause, cancer, and CVD mortality.
443 Moreover, we found that plasma omega-3 and omega-6 PUFAs were independently and
444 inversely associated with the three mortality outcomes, with omega-3 fatty acids showing
445 stronger inverse associations. Our findings support the active management of a high circulating
446 level of omega-3 fatty acids and a low omega-6/omega-3 ratio to prevent premature death.
447 Future research is warranted to further test the causality, such as Mendelian randomization and
448 randomized controlled trials. Mechanistic research, including comprehensive mediation analysis,
449 in-depth experimental characterization in animal models or cell lines, and intervention studies, is
450 also needed to unravel the molecular and physiological underpinnings.

451

452 **Declarations**

453 **Ethics approval and consent to participate**

454 The UK Biobank received ethical approval from the research ethics committee (reference ID: 11/
455 NW/0382). Written informed consent was obtained from participants.

456 **Consent for publication**

457 Not applicable.

458 **Availability of data and materials**

459 The datasets analyzed during the current study are available from the UK Biobank through an
460 application process (www.ukbiobank.ac.uk/).

461 **Competing interests**

462 The authors declare no competing interests.

463 **Funding**

464 Research reported in this publication was supported by the National Institute of General Medical
465 Sciences of the National Institute of Health under the award number R35GM143060 (KY). The
466 content is solely the responsibility of the authors and does not necessarily represent the official
467 views of the National Institutes of Health.

468 **Authors' contributions**

469 YZ performed data analysis, prepared visualizations, and wrote the original draft of the
470 manuscript. YS, QY, and SS contributed to the data analysis. YS (yeshen@uga.edu) and KY
471 (kaixiong.ye@uga.edu) contributed equally to this project and should be considered co-
472 corresponding authors. They jointly designed and supervised the project. JTB contributed to the
473 interpretations of results. All authors critically edited the manuscript for important intellectual

474 content. The corresponding author (KY) attests that all listed authors meet the authorship criteria
475 and that no others meeting the criteria were omitted.

476 **Acknowledgements**

477 This research has been conducted using the UK Biobank Resource under Application Number
478 48818. We would like to express our heartfelt gratitude to the UK Biobank participants and
479 administrative staff.

480

481 **Abbreviations**

95% CI	95% confidence interval
ANOVA	Analysis of variance
BMI	Body mass index
CRP	C-creative protein
CVD	Cardiovascular disease
DHA	Docosahexaenoic acid
DHA%	Docosahexaenoic acid to total fatty acids percentage
E2	Oestradiol
EPA	Eicosapentaenoic acid
HR	Hazard ratio
LA	Linoleic acid
LA%	Linoleic acid to total fatty acids percentage
IGF-1	Insulin-like growth factor 1
Omega-3%	Omega-3 fatty acids to total fatty acids percentage
Omega-6%	Omega-6 fatty acids to total fatty acids percentage
PUFAs	Polyunsaturated fatty acids
Ref	Reference
SD	Standard deviation
SHBG	Sex hormone binding globulin
TTST	Testosterone

482

483

484

485

486 **Supplementary Information**

487 **Additional file 1: Table S1.** Literature review.

488 **Additional file 2: Table S2.** Risk estimates of ratio of plasma omega-6 to omega-3 PUFAs with
489 all-cause, cancer and CVD mortality, stratified by potential risk factors, in the UK Biobank

490 Study. **Table S3.** Associations of plasma omega-3 PUFAs percentage with all-cause, cancer, and
491 CVD mortality risk in the UK Biobank Study. **Table S4.** Associations of plasma omega-6

492 PUFAs percentage with all-cause, cancer, and CVD mortality risk in the UK Biobank Study.

493 **Table S5.** Fully adjusted joint associations of plasma omega-3 PUFAs percentage and omega-6
494 PUFAs percentage with all-cause and cause-specific mortality in the UK Biobank Study. **Table**

495 **S6.** Associations of the dietary PUFAs with all-cause, cancer, and CVD mortality risk in the UK
496 Biobank. **Table S7.** Selected participants serum biochemical markers at baseline across quintiles

497 of the plasma omega-6/omega-3 PUFAs ratio. **Table S8.** Mediation analysis of biomarkers on

498 associations between plasma omega-6/omega-3 ratio and mortality. **Figure S1.** Directed acyclic

499 graph to explain mediation. **Table S9.** Associations of DHA and LA with all-cause, cancer, and

500 CVD mortality risk in the UK Biobank. **Table S10.** Associations of ratio of omega-6/omega-3

501 PUFAs with all-cause, cancer, and CVD mortality risk in the UK Biobank, covariates including

502 fish oil supplementation status. **Table S11.** Associations of ratio of omega-6/omega-3 PUFAs

503 with all-cause, cancer, and CVD mortality risk in the UK Biobank Study, with multiple

504 imputation for missing data. **Table S12.** Associations of ratio of omega-6/omega-3 PUFAs with

505 all-cause, cancer, and CVD mortality risk in the UK Biobank Study, excluding those who died in

506 the first follow-up year. **Table S13.** Baseline characteristics of participants with missing
507 exposure information and not included in the study.

508

509 **References**

- 510 1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries
511 and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
512 2019. *Lancet*. 2020;396(10258):1204-1222.
- 513 2. Harris WS. The omega-3 index: from biomarker to risk marker to risk factor. *Curr Atheroscler*
514 *Rep*. 2009;11(6):411-417.
- 515 3. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary
516 heart disease? *Prev Med*. 2004;39(1):212-220.
- 517 4. Harris WS, Luo J, Pottala JV, et al. Red blood cell polyunsaturated fatty acids and mortality
518 in the Women's Health Initiative Memory Study. *J Clin Lipidol*. 2017;11(1):250-259.e255.
- 519 5. Harris WS, Tintle NL, Etherton MR, Vasan RS. Erythrocyte long-chain omega-3 fatty acid
520 levels are inversely associated with mortality and with incident cardiovascular disease: The
521 Framingham Heart Study. *J Clin Lipidol*. 2018;12(3):718-727.e716.
- 522 6. Kleber ME, Delgado GE, Lorkowski S, März W, von Schacky C. Omega-3 fatty acids and
523 mortality in patients referred for coronary angiography. The Ludwigshafen Risk and
524 Cardiovascular Health Study. *Atherosclerosis*. 2016;252:175-181.
- 525 7. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for
526 Hypertriglyceridemia. *N Engl J Med*. 2019;380(1):11-22.
- 527 8. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil
528 on major adverse cardiovascular events in patients at high cardiovascular risk: the
529 STRENGTH randomized clinical trial. *JAMA*. 2020;324(22):2268-2280.
- 530 9. Delgado GE, März W, Lorkowski S, von Schacky C, Kleber ME. Omega-6 fatty acids:
531 opposing associations with risk-The Ludwigshafen Risk and Cardiovascular Health Study. *J*
532 *Clin Lipidol*. 2017;11(4):1082-1090.e1014.
- 533 10. Marklund M, Wu JHY, Imamura F, et al. Biomarkers of dietary omega-6 fatty acids and
534 incident cardiovascular disease and mortality. *Circulation*. 2019;139(21):2422-2436.
- 535 11. Wu JHY, Lemaitre RN, King IB, et al. Circulating omega-6 polyunsaturated fatty acids and
536 total and cause-specific mortality. *Circulation*. 2014;130(15):1245-1253.
- 537 12. Harris K, Oshima M, Sattar N, et al. Plasma fatty acids and the risk of vascular disease and
538 mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study.
539 *Diabetologia*. 2020;63(8):1637-1647.
- 540 13. Miura K, Hughes MCB, Ungerer JPJ, Green AC. Plasma eicosapentaenoic acid is negatively
541 associated with all-cause mortality among men and women in a population-based
542 prospective study. *Nutr Res*. 2016;36(11):1202-1209.
- 543 14. Otsuka R, Tange C, Nishita Y, et al. Fish and meat intake, serum eicosapentaenoic acid and
544 docosahexaenoic acid levels, and mortality in community-dwelling Japanese older persons.
545 *Int J Environ Res Public Health*. 2019;16(10).

- 546 15. Zhuang P, Wang W, Wang J, Zhang Y, Jiao J. Polyunsaturated fatty acids intake, omega-
547 6/omega-3 ratio and mortality: Findings from two independent nationwide cohorts. *Clin Nutr*.
548 2019;38(2):848-855.
- 549 16. Shim JS, Oh K, Kim HC. Dietary assessment methods in epidemiologic studies. *Epidemiol*
550 *Health*. 2014;36:e2014009.
- 551 17. Simopoulos AP. Evolutionary aspects of diet and essential fatty acids. *World Rev Nutr Diet*.
552 2001;88:18-27.
- 553 18. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular
554 disease and other chronic diseases. *Exp Biol Med*. 2008;233(6):674-688.
- 555 19. Noori N, Dukkipati R, Kovesdy CP, et al. Dietary omega-3 fatty acid, ratio of omega-6 to
556 omega-3 intake, inflammation, and survival in long-term hemodialysis patients. *Am J of*
557 *Kidney Dis*. 2011;58(2):248-256.
- 558 20. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying
559 the causes of a wide range of complex diseases of middle and old age. *PLOS Med*.
560 2015;12(3):e1001779.
- 561 21. Julkunen H, Cichońska A, Tiainen M, et al. Atlas of plasma NMR biomarkers for health and
562 disease in 118,461 individuals from the UK Biobank. *Nat Commun*. 2023 Feb 3;14(1):604.
563 doi: 10.1038/s41467-023-36231-7.
- 564 22. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative
565 serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -
566 Omic technologies. *Am J Epidemiol*. 2017;186(9):1084-1096.
- 567 23. Perez-Cornago A, Pollard Z, Young H, et al. Description of the updated nutrition calculation
568 of the Oxford WebQ questionnaire and comparison with the previous version among 207,144
569 participants in UK Biobank. *Eur J Nutr*. 2021;60(7):4019-4030.
- 570 24. Chua ME, Sio MC, Sorongon MC, Dy JS. Relationship of dietary intake of omega-3 and
571 omega-6 Fatty acids with risk of prostate cancer development: a meta-analysis of
572 prospective studies and review of literature. *Prostate Cancer*. 2012;2012:826254.
- 573 25. Durrleman S, Simon R. Flexible regression models with cubic splines. *Stat Med*.
574 1989;8(5):551-561.
- 575 26. Li Z-H, Zhong W-F, Liu S, et al. Associations of habitual fish oil supplementation with
576 cardiovascular outcomes and all cause mortality: evidence from a large population based
577 cohort study. *BMJ*. 2020;368:m456.
- 578 27. Zhang Y, Zhuang P, He W, et al. Association of fish and long-chain omega-3 fatty acids
579 intakes with total and cause-specific mortality: prospective analysis of 421 309 individuals. *J*
580 *Intern Med*. 2018;284(4):399-417.
- 581 28. Lapointe-Shaw L, Bouck Z, Howell NA, et al. Mediation analysis with a time-to-event
582 outcome: a review of use and reporting in healthcare research. *BMC Medical Research*
583 *Methodology*. 2018;18(1):118.
- 584 29. Valeri L, VanderWeele TJ. SAS Macro for Causal Mediation Analysis with Survival Data.
585 *Epidemiology*. 2015;26(2):e23-e24.
- 586 30. VanderWeele TJ. Causal mediation analysis with survival data. *Epidemiology*.
587 2011;22(4):582-585.
- 588 31. van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations
589 in R. *J Stat Softw*. 2011;45(3):1 - 67.
- 590 32. Murff HJ, Tindle HA, Shrubsole MJ, et al. Smoking and red blood cell phospholipid
591 membrane fatty acids. *Prostaglandins Leukot Essent Fatty Acids*. 2016;112:24-31.

- 592 33. Scaglia N, Chatkin J, Chapman KR, et al. The relationship between omega-3 and smoking
593 habit: a cross-sectional study. *Lipids Health Dis.* 2016;15:61.
- 594 34. Chen GC, Yang J, Eggersdorfer M, Zhang W, Qin LQ. N-3 long-chain polyunsaturated fatty
595 acids and risk of all-cause mortality among general populations: a meta-analysis. *Sci Rep.*
596 2016;6:28165.
- 597 35. Eide IA, Dahle DO, Svensson M, et al. Plasma levels of marine n-3 fatty acids and
598 cardiovascular risk markers in renal transplant recipients. *Eur J Clin Nutr.* 2016;70(7):824-
599 830.
- 600 36. Harris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and total and cause-
601 specific mortality from 17 prospective studies. *Nat Commun.* 2021;12(1):2329.
- 602 37. Lee S-H, Shin M-J, Kim J-S, et al. Blood eicosapentaenoic acid and docosahexaenoic acid
603 as predictors of all-cause mortality in patients with acute myocardial infarction-data from
604 Infarction Prognosis Study (IPS) Registry. *Circ J.* 2009;73(12):2250-2257.
- 605 38. Lindberg M, Saltvedt I, Sletvold O, Bjerve KS. Long-chain n-3 fatty acids and mortality in
606 elderly patients. *Am J Clin Nutr.* 2008;88(3):722-729.
- 607 39. Pertiwi K, Küpers LK, Goede Jd, Zock PL, Kromhout D, Geleijnse JM. Dietary and circulating
608 long-chain omega-3 polyunsaturated fatty acids and mortality risk after myocardial infarction:
609 a long-term follow-up of the Alpha Omega Cohort. *J Am Heart Assoc.* 2021;10(23):e022617.
- 610 40. Pottala JV, Garg S, Cohen BE, Whooley MA, Harris WS. Blood eicosapentaenoic and
611 docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart
612 disease: the Heart and Soul study. *Circ Cardiovasc Qual Outcomes.* 2010;3(4):406-412.
- 613 41. Miura K, Hughes MCB, Ungerer JPJ, Smith DD, Green AC. Absolute versus relative
614 measures of plasma fatty acids and health outcomes: example of phospholipid omega-3 and
615 omega-6 fatty acids and all-cause mortality in women. *Eur J Nutr.* 2018;57(2):713-722.
- 616 42. Warensjö E, Sundström J, Vessby B, Cederholm T, Risérus U. Markers of dietary fat quality
617 and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-
618 based prospective study. *Am J Clin Nutr.* 2008;88(1):203-209.
- 619 43. de Lorgeril M, Renaud S, Salen P, et al. Mediterranean alpha-linolenic acid-rich diet in
620 secondary prevention of coronary heart disease. *Lancet.* 1994;343(8911):1454-1459.
- 621 44. Petrone AB, Weir N, Hanson NQ, et al. Omega-6 fatty acids and risk of heart failure in the
622 Physicians' Health Study. *Am J Clin Nutr.* 2012;97(1):66-71.
- 623 45. Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Akabane M, Tsugane S. Single
624 measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake in
625 middle-aged Japanese men. *Eur J Clin Nutr.* 2001;55(8):643-650.
- 626 46. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to
627 regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol.*
628 1999;150(4):341-353.
- 629 47. Batty, G. D., Gale, C. R., Kivimäki, M., Deary, I. J., & Bell, S. Comparison of risk factor
630 associations in UK Biobank against representative, general population based studies with
631 conventional response rates: prospective cohort study and individual participant meta-
632 analysis. *BMJ.* 2020; 368: m131.
- 633 48. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE.
634 Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
635 Participants With Those of the General Population. *Am J Epidemiol.* 2017;186(9):1026–34.

Tables

Table 1. Selected participants characteristics at baseline across quintiles of the plasma omega-6/omega-3 PUFAs ratio (n=85,425).

Characteristics ^a	Omega-6/omega-3 ratio quintiles					P
	1 (median = 5.9) (n = 17,085)	2 (median = 7.6) (n = 17,085)	3 (median = 9.1) (n = 17,085)	4 (median = 11.0) (n = 17,085)	5 (median = 14.8) (n = 17,085)	
Age (years)	58.6 (7.5)	57.2 (7.9)	55.7 (8.2)	54.7 (8.3)	53.4 (8.2)	<0.001 ^b
Sex (male%)	40.3	44.9	47.5	49.4	52.8	<0.001 ^c
Ethnicity(n%)						
White	15,375 (90.4%)	15,486 (91.0%)	15,494 (91.1%)	15,467 (91.1%)	15,420 (90.7%)	0.384 ^c
Black	113 (0.7%)	99 (0.6%)	105 (0.6%)	92 (0.5%)	116 (0.7%)	
Asian	673 (4.0%)	639 (3.8%)	663 (3.9%)	653 (3.8%)	659 (3.9%)	
Others	844 (5.0%)	786 (4.6%)	742 (4.4%)	773 (4.6%)	810 (4.8%)	
Missing (n)	80	75	81	100	80	
BMI	27.0 (4.4)	27.3 (4.5)	27.3 (4.7)	27.3 (4.8)	26.9 (5.0)	<0.001 ^b
Missing (n)	54	64	55	58	71	
TDI	-1.6 (3.0)	-1.5 (3.0)	-1.4 (3.1)	-1.2 (3.1)	-0.9 (3.2)	<0.001 ^b
Missing (n)	17	24	24	28	22	
Smoking status (n%)						<0.001 ^c
Never	9,426 (55.5%)	9,272 (54.6%)	9,424 (55.4%)	9,400 (55.3%)	9,214 (54.2%)	
Previous	6,402 (37.7%)	6,194 (36.5%)	5,772 (34.0%)	5,492 (32.3%)	4,951 (29.1%)	
Current	1,162 (6.8%)	1,526 (9.0%)	1,802 (10.6%)	2,104 (12.4%)	2,832 (16.7%)	
Missing (n)	95	93	87	89	88	
Alcohol status (n%)						<0.001 ^c
Never	631 (3.7%)	676 (4.0%)	655 (3.8%)	755 (4.4%)	974 (5.7%)	
Previous	536 (3.1%)	554 (3.2%)	535 (3.1%)	617 (3.6%)	835 (4.9%)	
Current	15,877 (93.2%)	15,822 (92.8%)	15,847 (93.0%)	15,664 (91.9%)	15,221 (89.4%)	
Missing (n)	41	33	48	49	55	
Physical activity (n%)						<0.001 ^c
Low	2,422 (17.4%)	2,602 (18.8%)	2,653 (19.1%)	2,617 (19.0%)	2,613 (18.9%)	
Moderate	5,879 (42.2%)	5,762 (41.5%)	5,712 (41.1%)	5,533 (40.1%)	5,327 (38.6%)	
High	5,635 (40.4%)	5,506 (39.7%)	5,545 (39.9%)	5,654 (41.0%)	5,854 (42.4%)	
Missing (n)	3,149	3,215	3,175	3,281	3,291	

Fish oil supplementation (Yes%)	48.1	37.7	29.6	22.7	15.5	<0.001 ^c
<i>Missing (n)</i>	50	47	77	82	71	
Comorbidity (Yes%)	38.6	37.3	34.2	33.8	33.0	<0.001 ^c
Plasma omega-3 percentage	6.6 (1.4)	4.9 (0.5)	4.2 (0.4)	3.5 (0.3)	2.6 (0.5)	<0.001 ^b
Plasma omega-6 percentage	36.3 (3.7)	37.4 (3.4)	38.2 (3.3)	39.1 (3.2)	40.2 (3.1)	<0.001 ^b
Plasma DHA percentage	2.8 (0.8)	2.1 (0.5)	1.9 (0.4)	1.7 (0.4)	1.5 (0.4)	<0.001 ^b
Plasma LA percentage	27.0 (3.3)	28.4 (3.1)	29.3 (3.0)	30.2 (3.0)	31.3 (3.1)	<0.001 ^b
Dietary omega-3 percentage	3.6 (1.8)	3.2 (1.4)	3.0 (1.3)	2.9 (1.2)	2.7 (1.0)	<0.001 ^b
<i>Missing (n)</i>	9,355	9,628	9,857	9,974	10,288	
Dietary omega-6 percentage	16.8 (4.6)	16.5 (4.4)	16.6 (4.6)	16.5 (4.7)	16.5 (4.8)	<0.001 ^b
<i>Missing (n)</i>	9,355	9,628	9,857	9,974	10,288	

^a All variables measured at baseline are presented as mean (SD) unless otherwise specified.

^b From the ANOVA test for continuous variables.

^c From the Pearson's Chi-squared test for categorical variables.

Table 2. Associations^a of the plasma omega-6/omega-3 PUFAs ratio with all-cause, cancer, and CVD mortality risk in the UK Biobank.

Omega ratio variable forms	Causes of death								
	All-cause			Cancer			Cardiovascular diseases		
	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c
		HR (95% CI)	HR (95% CI)		HR (95% CI)	HR (95% CI)		HR (95% CI)	HR (95% CI)
Continuous	6,461	1.02 (1.02-1.03)	1.02 (1.02-1.03)	2,794	1.02 (1.01-1.03)	1.01 (1.00-1.02)	1,668	1.02 (1.01-1.03)	1.02 (1.01-1.03)
Quintiles (median)									
1 (5.9)	1,348	1.00 (ref)	1.00 (ref)	593	1.00 (ref)	1.00 (ref)	369	1.00 (ref)	1.00 (ref)
2 (7.6)	1,256	1.00 (0.92-1.08)	0.96 (0.88-1.05)	563	1.02 (0.91-1.15)	0.98 (0.86-1.12)	315	0.90 (0.77-1.05)	0.89 (0.75-1.06)
3 (9.1)	1,236	1.06 (0.98-1.15)	1.01 (0.93-1.11)	543	1.08 (0.96-1.21)	0.99 (0.87-1.13)	321	0.97 (0.84-1.13)	0.97 (0.81-1.16)
4 (11.0)	1,252	1.14 (1.06-1.23)	1.09 (1.00-1.19)	548	1.16 (1.03-1.31)	1.12 (0.98-1.27)	306	0.98 (0.84-1.15)	1.02 (0.86-1.22)
5 (14.8)	1,369	1.34 (1.24-1.45)	1.26 (1.15-1.38)	547	1.27 (1.12-1.43)	1.14 (1.00-1.31)	357	1.20 (1.04-1.40)	1.31 (1.10-1.55)
<i>P</i> _{trend}		<0.001	<0.001		<0.001	0.011		0.002	<0.001

Abbreviations: CI, confidence interval; HR, hazards ratio; ref, reference.

^a From Cox proportional hazards regression.

^b Adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre.


^c Adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure Legends

Figure 1. Risk estimates of all-cause mortality for the highest compared with the lowest quintile of the ratio of plasma omega-6 to omega-3 PUFAs, stratified by potential risk factors. Results were adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure 2. Risk estimates of cause-specific mortality for the highest compared with the lowest quintile of the ratio of plasma omega-6 to omega-3 PUFAs, stratified by potential risk factors. Results were adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure 3. Associations of the ratio of omega-6/omega-3 PUFAs with all-cause and cause-specific mortality evaluated using restricted cubic splines. Hazard ratios and omega ratios are presented in the vertical and horizontal axis, respectively. The best estimates and their confidence intervals are presented as solid red lines and dotted black lines, respectively. The ratio 4 was selected as a reference level, and the x-axis depicts the ratio from 0 to 40. Potential nonlinearity was identified for all-cause mortality ($p < 0.05$) and CVD-caused mortality ($p < 0.05$), but not for cancer-caused mortality ($p = 0.12$). All HRs are adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m²; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).




Cancer Mortality

CVD Mortality


Subgroup	No. of Participants	No. of Death (%)	Hazard Ratio (95% CI)	P value for interaction	No. of Death (%)	Hazard Ratio (95% CI)	P value for interaction
Overall	17,085	547 (3.2)	1.14 (1.00-1.31)		357 (2.09)	1.31 (1.10-1.55)	
Age (years)				0.85			0.56
< 58	11,146	188 (1.69)	1.07 (0.80-1.43)		112 (1)	1.11 (0.77-1.61)	
>= 58	5,939	359 (6.04)	1.04 (0.89-1.21)		245 (4.13)	1.24 (1.02-1.51)	
Sex				0.33			0.73
Male	9,020	355 (3.94)	1.17 (0.98-1.40)		282 (3.13)	1.31 (1.08-1.60)	
Female	8,065	192 (2.38)	1.11 (0.89-1.38)		75 (0.93)	1.31 (0.91-1.88)	
TDI				0.4			0.83
< -2	7,823	240 (3.07)	1.06 (0.88-1.28)		121 (1.55)	1.35 (1.04-1.75)	
>= -2	9,240	307 (3.32)	1.29 (1.06-1.58)		235 (2.54)	1.32 (1.05-1.66)	
BMI (kg/m ²)				0.78			0.62
< 25	6,673	184 (2.76)	1.04 (0.81-1.34)		97 (1.45)	1.32 (0.93-1.88)	
>= 25	10,341	362 (3.5)	1.19 (1.01-1.40)		257 (2.49)	1.30 (1.07-1.59)	
Comorbidity				0.74			<0.001
Yes	5,639	282 (5)	1.12 (0.93-1.35)		250 (4.43)	1.24 (1.01-1.52)	
No	11,446	265 (2.32)	1.17 (0.96-1.43)		107 (0.93)	1.47 (1.05-2.06)	
Physical Activity				0.99			0.16
Low or Moderate	7,940	247 (3.11)	1.17 (0.98-1.39)		180 (2.27)	1.37 (1.10-1.70)	
High	5,854	165 (2.82)	1.11 (0.89-1.38)		100 (1.71)	1.22 (0.91-1.62)	
Current Smoking Status				0.13			0.12
Yes	2,832	176 (6.21)	1.41 (1.01-1.97)		116 (4.1)	2.09 (1.33-3.27)	
No	14,165	367 (2.59)	1.06 (0.91-1.23)		238 (1.68)	1.18 (0.97-1.43)	

<https://doi.org/10.1101/2023.01.16.23284631>; this version posted January 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.


All-cause Mortality



Cancer Mortality



CVD Mortality



esuecuj jnoitivy eulj 6 7 CN 18 20 g. repun eiqelle/ve epew si tl
'e ax Rpeu peisod uoisreA sui : 15948252 91 : 10 5207/1011 : 01/0100/150
'4Z07 '01 Aenuec peisod uoisreA sui : 15948252 91 : 10 5207/1011 : 01/0100/150
the
display the
equi
0uAAdoc eu1